04.06.20 - GSK announces new data presentations from the DREAMM program exploring investigational belantamab mafodotin in patients with relapsed/ refractory multiple myeloma

Pressemitteilung der GlaxoSmithKlince plc
GlaxoSmithKline (GSK) plc today announced new data from its DREAMM (DRiving Excellence in Approaches to Multiple Myeloma) clinical trial programme of belantamab mafodotin in relapsed/refractory multiple myeloma will be presented at the upcoming virtual edition of the 25th European Hematology Association (EHA) Annual Congress from 11-21 June 2020.

Zuletzt aufgerufen am: 22.10.2020 16:24